Skip to main content

Alport Syndrome clinical trials at University of California Health

1 in progress, 0 open to eligible people

Showing trials for
  • Atrasentan in Patients With Proteinuric Glomerular Diseases

    Sorry, in progress, not accepting new patients

    The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

    at UCLA

Our lead scientists for Alport Syndrome research studies include .